Navigation Links
Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
Date:7/16/2008

LOS ANGELES, July 16 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has initiated coverage on MediciNova Inc. (Nasdaq: MNOV). "MediciNova has a promising drug development pipeline for treating a variety of diseases and conditions. The Company is primarily focused on two drug development programs; the first is MN-221 for the treatment of Status Asthmaticus. There are an estimated 2,000,000 visits to the emergency room a year for asthma related difficulties. The market for treatment of asthma related difficulties is in the billions and we believe MN-221, if approved, will garner a sizable percentage of the market potentially resulting in hundreds of millions of dollars in sales for MediciNova. The second drug in development is MN-166 for the treatment of multiple sclerosis (MS). MS is believed to affect approximately 350,000 to 400,000 people in the United States and over 2.5 million globally. Worldwide sales of drugs used in the treatment of MS were approximately $7.2 billion in 2006," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About MediciNova, Inc.:

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, an acute, severe asthma attack, and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit http://www.medicinova.com.

Contact:

Vista Partners LLC

Sherry Watkins

(310)744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , ... September 19, 2017 , ... ... largest group of funded early-stage tech companies. “Grit” author Angela Duckworth and her ... joining the ic@3401 community is Cooley, an international law firm with decades of ...
(Date:9/19/2017)... ... September 19, 2017 , ... One ... about to be eliminated, said Lyle Probst, President, CEO and Founder of ... different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside ...
(Date:9/19/2017)... ... 19, 2017 , ... Molecular Devices, LLC, a leader in ... launch the CloneSelect™ Single-Cell Printer™ in North America. This novel system utilizes ... visual documentation of monoclonality for use in cell line development. , Clonal ...
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass ... briquettes, and torrefied wood is the topic of a September 27 webinar ... potential economic viability of transportable biomass conversion facilities for producing biochar, briquettes, and ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):